Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;12(5):R76.
doi: 10.1186/bcr2719. Epub 2010 Sep 28.

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

Affiliations

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

Isabel F Pinhel et al. Breast Cancer Res. 2010.

Abstract

Introduction: Very few studies have investigated whether the time elapsed between surgical resection and tissue fixation or the difference between core-cut and excision biopsies impact on immunohistochemically measured biomarkers including phosphorylated proteins in primary breast cancer. The aim of this study was to characterize the differences in immunoreactivity of common biomarkers that may occur (a) due to tissue handling at surgery and (b) between core-cuts and resected tumours.

Methods: Core-cuts taken from surgical breast cancer specimens immediately after resection (sample A) and after routine X-ray of the excised tumour (sample B) were formalin-fixed and paraffin-embedded and compared to the routinely fixed resection specimen (sample C). The variation in immunohistochemical expression of Ki67, oestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor 2 (HER2), p-Akt and p-Erk were investigated.

Results: Twenty-one tissue sets with adequate tumour were available. Median time between collection of core-cuts A and B was 30 minutes (range 20 to 80). None of the markers showed significant differences between samples A and B. Similarly, Ki67, ER, PgR and HER2 did not differ significantly between core-cuts and main resection specimen although there was a trend for lower resection values for ER (P=0.06). However, p-Akt and p-Erk1/2 were markedly lower in resections than core-cuts (median 27 vs 101 and 69 vs 193, respectively; both P<0.0001 [two-sided]). This difference was significantly greater in mastectomy than lumpectomy specimens for p-Erk1/2 (P=0.01).

Conclusions: The delay in fixation in core-cuts taken after post-operative X-ray of resection specimens has no significant impact on expression of Ki67, ER, PgR, HER2, p-Akt or p-Erk1/2. However extreme loss of phospho-staining can occur during routine fixation of resection specimens. These differences are likely attributable to suboptimal fixation and may have major repercussions for clinical research involving these markers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression of commonly assessed markers in breast cancer specimens by immunohistochemistry (IHC). Expression of (a) Ki67, (b) ER, (c) PgR and (d) HER2 in core-cuts (mean of samples A and B) and resections (sample C).
Figure 2
Figure 2
Expression of phosphoproteins in core-cuts and excisions according to type of surgical specimen. (a) p-Akt and (b) p-Erk1/2 expression by IHC in core-cuts (mean of samples A and B) and resection (sample C).
Figure 3
Figure 3
Expression of p-Akt and p-Erk1/2 in lumpectomy versus mastectomy specimens. Percentage difference between resections (sample C) and core-cuts (mean of samples A and B) expression values for (a) p-Akt and (b) p-Erk1/2. Percentage difference defined as (sample C - mean of samples A and B) × 100/mean of samples A and B.

Similar articles

Cited by

References

    1. Dowsett M. Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res. 2003;9:502s. - PubMed
    1. Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007;25:3816–3822. doi: 10.1200/JCO.2006.09.6578. - DOI - PubMed
    1. Baker AF, Dragovich T, Ihle NT, William R, Fenoglio-Presiser C, Powis G. Stability of phosphoprotein as a biological marker of tumour signalling. Clin Cancer Res. 2005;11:4338–4340. doi: 10.1158/1078-0432.CCR-05-0422. - DOI - PubMed
    1. De Cecco L, Musella V, Veneroni S, Cappelletti V, Bongarzone I, Callari M, Valeri B, Pierotti MA, Daidone MG. Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer. 2009;9:409. doi: 10.1186/1471-2407-9-409. - DOI - PMC - PubMed
    1. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LS, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol. 2007;25:118–145. doi: 10.1200/JCO.2006.09.2775. - DOI - PubMed

Publication types